Fiscal impact reports (FIRs) are prepared by the Legislative Finance Committee (LFC) for standing finance
committees of the NM Legislature. The LFC does not assume responsibility for the accuracy of these reports
if they are used for other purposes.
Current FIRs (in HTML & Adobe PDF formats) are a vailable on the NM Legislative Website (legis.state.nm.us).
Adobe PDF versions include all attachments, whereas HTML versions may not. Previously issued FIRs and
attachments may be obtained from the LFC in Suite 101 of the State Capitol Building North.
F I S C A L I M P A C T R E P O R T
SPONSOR
HHGAC
ORIGINAL DATE
LAST UPDATED
01/29/08
02/06/08 HM 34/HHGACS
SHORT TITLE
Study Antidepressants and Suicide
SB
ANALYST Hanika-Ortiz
ESTIMATED ADDITIONAL OPERATING BUDGET IMPACT (dollars in thousands)
FY08
FY09
FY10 3 Year
Total Cost
Recurring
or Non-Rec
Fund
Affected
Total
$0.1
Recurring General
Fund
(Parenthesis ( ) Indicate Expenditure Decreases)
SOURCES OF INFORMATION
LFC Files
SUMMARY
Synopsis of Bill
House Memorial 34 requests the Health Policy Commission convene an expert task force to
study the correlation between antidepressant use and suicidal thoughts and behaviors and to
recommend solutions to address any correlation.
If a correlation exists, the task force will further examine mandatory continuing medical
education courses for providers prescribing antidepressants in young people.
FISCAL IMPLICATIONS
Agencies will have expenditures in providing staff time to support the task force.
The task force will be required to consult with regional and national experts in children’s
behavioral health to review relevant regulatory and statutory issues on whether a correlation
exists and provide recommendations for best practice in the area of antidepressant
pharmaceutical use in children and adolescents.
SIGNIFICANT ISSUES
The literature on the link between antidepressant use in children, and suicides and/or suicidal
behavior is inconsistent as to whether there is a link.
DOH reports that debate continues at the national level as to the effectiveness of prescription
antidepressant use in adolescents. The Federal Food and Drug Administration has issued public